Literature DB >> 9128776

Prediction of pathological subtrochanteric fractures due to metastatic lesions.

P D Dijkstra1, M Oudkerk, T Wiggers.   

Abstract

We report a radiographic review of 54 consecutive patients with 24 impending and 30 actual pathological fractures due to metastatic bone lesions in the subtrochanteric femoral region. In an attempt to develop criteria for metastatic lesions at risk of fracturing, the following variables based on anteroposterior and lateral X-rays were considered: appearance of the lesion, width of the lesion, ratio between width of the lesion and bone width, length of the lesion, length of cortex involvement, proportion of transverse cortical bone destroyed and local pain. Nearly all (99%) of the lesions were radiographically classified as lytic. In 27 cases (50%) they were radiographically unmeasurable. Maximal longitudinal cortical destruction showed a difference between patients with an actual or impending fracture. Prophylactic internal fixation of pathological subtrochanteric fractures due to metastatic lesions has to be considered in cases of increasing pain. If the conventional X-ray can not be evaluated, a computed tomography (CT) scan has to be considered.

Entities:  

Mesh:

Year:  1997        PMID: 9128776     DOI: 10.1007/bf00393714

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  9 in total

1.  Subtrochanteric metastatic lesions treated with the long gamma nail.

Authors:  S R Samsani; V Panikkar; D Georgiannos; D Calthorpe
Journal:  Int Orthop       Date:  2003-06-11       Impact factor: 3.075

2.  Imaging and Clinical Characteristics Predict Near-Term Disablement From Bone Metastases: Implications for Rehabilitation.

Authors:  Andrea L Cheville; Naveen S Murthy; Jeffrey R Basford; Peter S Rose; Kenny Tran; Thomas P Pittelkow; Michael D Ringler
Journal:  Arch Phys Med Rehabil       Date:  2015-10-03       Impact factor: 3.966

Review 3.  Fear of impending fractures: when to refer? A case-based review.

Authors:  Caroline Kronisch; Federico Balagué; Jean Dudler
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

Review 4.  The effects of metastatic lesion on the structural determinants of bone: Current clinical and experimental approaches.

Authors:  Stacyann Bailey; David Hackney; Deepak Vashishth; Ron N Alkalay
Journal:  Bone       Date:  2019-11-21       Impact factor: 4.398

5.  Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation: a retrospective study.

Authors:  Zuzana Tatar; Martin Soubrier; Anne Françoise Dillies; Pierre Verrelle; Stéphane Boisgard; Michel Lapeyre
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

6.  The insufficiencies of risk analysis of impending pathological fractures in patients with femoral metastases: A literature review.

Authors:  Emir Benca; Janina M Patsch; Winfried Mayr; Dieter H Pahr; Reinhard Windhager
Journal:  Bone Rep       Date:  2016-03-02

7.  Limited short-term effect of palliative radiation therapy on quantitative computed tomography-derived bone mineral density in femora with metastases.

Authors:  Florieke Eggermont; Loes C Derikx; Nico Verdonschot; Gerjon Hannink; Robert S J P Kaatee; Esther Tanck; Yvette M van der Linden
Journal:  Adv Radiat Oncol       Date:  2016-11-10

8.  QCT-based finite element prediction of pathologic fractures in proximal femora with metastatic lesions.

Authors:  Emir Benca; Alexander Synek; Morteza Amini; Franz Kainberger; Lena Hirtler; Reinhard Windhager; Winfried Mayr; Dieter H Pahr
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

9.  Evaluation of inter- and intra-operator reliability of manual segmentation of femoral metastatic lesions.

Authors:  Ali Ataei; Florieke Eggermont; Milan Baars; Yvette van der Linden; Jacky de Rooy; Nico Verdonschot; Esther Tanck
Journal:  Int J Comput Assist Radiol Surg       Date:  2021-07-15       Impact factor: 2.924

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.